• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
    • Compliance Declaration
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Menin Inhibition
    • Farnesyl Transferase Inhibitors
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Our Medicine
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Kura Kommentary

AML World Awareness Day and Kura’s Commitment

2025 AML World Awareness Day

Our team supported Know AML in spreading awareness on the impact of AML for patients and their caregivers. Be sure to check out our team representing the AML community and AML World Awareness Day!

Thank you to our partners at Know AML for recognizing this important day and for your dedication to patients and their families throughout the year.

Kura’s Commitment to the AML Patient Community

AML is a type of blood cancer that starts in the bone marrow, and impacts the development of red blood cells, white blood cells, and platelets. As the most common form of leukemia in adults, there are about 120,000 new cases of AML per year globally.

Kura Oncology remains committed to the AML community, working as one for patients in developing potential new treatments for AML.

To learn more about our commitment to AML patients from early research to advocacy partnerships, watch the full video here.

Back to News & Media
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Grants & Funding
  • Investigator Sponsored Studies
  • Compliance Declaration
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Menin Inhibition
  • Farnesyl Transferase Inhibitors
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Our Medicine
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
4930 Directors Place, Suite 500
San Diego, CA 92121
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy | Cookie Policy | Consumer Health Data

Scroll to top Scroll to top Scroll to top